Literature DB >> 6086213

Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.

R Bolivar, S S Weaver, G P Bodey.   

Abstract

Thirty-eight isolates of gram-negative bacilli resistant to four new beta-lactam antibiotics, aztreonam, moxalactam, ceftazidime, and cefoperazone, were tested in the presence of two beta-lactam inhibitors, clavulanic acid and sulbactam. Microorganisms tested included 22 isolates of Pseudomonas species, 5 of Klebsiella species, and 11 of Enterobacter species. A 2- to 10-fold decrease in minimum inhibitory concentration was noted when antibiotics and beta-lactamase inhibitors were combined compared to antibiotics alone. Four strains of Pseudomonas aeruginosa showed increased resistance to the combination of antibiotics and beta-lactamase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086213     DOI: 10.1016/0732-8893(84)90039-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa.

Authors:  F Tausk; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  G P Bodey; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.

Authors:  P H Chandrasekar; J A Sluchak
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 4.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 5.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.